Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPRG.L Regulatory News (PRG)

  • There is currently no data for PRG

Appointments

5 Dec 2006 07:03

Premier Research Group05 December 2006 For Immediate Release 5 December 2006 PREMIER RESEARCH GROUP plc Premier Research appoints Peter Malamis as the President & General Manager of US Operations Premier Research Group plc (AIM: PRG) ("Premier Research", "Company" or"Group"), the international pharmaceutical services group today announces theappointment of Peter Malamis as the President & General Manager - US Operations. Mr. Malamis' responsibility with Premier Research will be the continued growthand development of the US business. Mr. Malamis was previously with SCIREXCorporation in the position of Senior Vice President & General Manager,Commercial Operations. The Company acquired SCIREX as a wholly-owned subsidiaryin July of this year. His more than 20 years of experience in the pharmaceuticalservices industry spans all phases of product development and commercialization.He joined SCIREX from Galt Associates where he was Vice President of Sales.Prior to Galt, Mr. Malamis held executive positions with MEDTAP International,PAREXEL International, State & Federal Associates and SYNTHESIS. Mr. Malamisobtained his B.A. in Political Science at the University of Richmond and hisM.B.A. in Marketing from George Washington University. He also currently servesas a Board member and advisor to several early-stage pharmaceutical servicescompanies. Dr. John Gilly, Chief Operating Officer of Premier Research Group plc,commented: "We are extremely pleased to have Peter join us in this criticallyimportant role. The Company has increased in depth and therapeutic focus overthe past three years and we expect Peter's experience to contribute greatly tofurther commercial success." Said Mr., Malamis, "I'm looking forward to building the US CRO operation;respected for its expertise, commitment to the customer, quality, andreliability. Our clients are engaged in research critically important tomillions of people. They deserve the best service possible and we intend to giveit to them through our talented, dedicated employees." Enquiries:Premier Research Group plc Dr Simon Yaxley, Chief Executive Officer Tel: 01344 752375 Bernard Gallagher, Chief Financial Officer Tel: 01344 458309www.premier-research.com Buchanan Communications Tel: 020 7466 5000 Lisa Baderoon Rebecca Skye Dietrich About Premier Research Premier Research is dedicated to being a leading solutions-driven CRO leveragingour commitment to therapeutic focus and scientific expertise to deliver servicesof the highest quality for Phase I-IV clinical trials. Premier Research is aleader in clinical research for Analgesia, CNS, Infectious Disease and Oncologyand has a wealth of experience in pediatric research. Premier Research has 28 offices and operates in more than 30 countries acrossEurope and North America. Premier Research employs more than 750 clinicalprofessionals dedicated first and foremost to fulfilling each client'srequirements in a timely, accurate and cost-effective manner. This includes astrong international network of monitors and project management professionalscombined with regulatory, data management, statistical, scientific and medicalexperts, and staff at our well-established network of dedicated clinical sites. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Jan 20089:39 amRNSEPT Disclosure
18th Jan 20083:57 pmRNSRule 8.3- (Premier Research)
18th Jan 20089:16 amRNSEPT Disclosure
17th Jan 200811:25 amRNSRule 8.3- Premier Research
17th Jan 200810:43 amRNSEPT Disclosure
16th Jan 200810:11 amRNSEPT Disclosure
15th Jan 20082:49 pmPRNRule 8.3 - Premier Research
15th Jan 20088:06 amRNSEPT Disclosure
14th Jan 20083:07 pmPRNRule 8.3 - Premier Research plc
14th Jan 20088:40 amRNSEPT Disclosure
11th Jan 20089:24 amRNSEPT Disclosure
11th Jan 20089:06 amRNSRule 8.3- Premier Research
10th Jan 20089:10 amRNSRule 8.3- Premier Research
10th Jan 20088:58 amRNSEPT Disclosure
9th Jan 20083:25 pmRNSRule 8.3- Premier Research
9th Jan 200811:57 amRNSRule 8.3- Premier Research
9th Jan 200811:51 amRNSRule 8.3- Premier Research
9th Jan 200811:34 amRNSRule 8.3-PremierResearch-Amnd
9th Jan 20089:06 amRNSRule 8.3- Premier Research
9th Jan 20088:32 amRNSEPT Disclosure
8th Jan 20082:47 pmPRNRule 8.3 - Premier Research
8th Jan 200811:17 amRNSEPT Disclosure
8th Jan 200810:27 amRNSRule 8.3- Premier Research
7th Jan 20088:59 amRNSEPT Disclosure
4th Jan 200810:21 amRNSRule 8.3- Premier Research
4th Jan 20088:19 amRNSEPT Disclosure
3rd Jan 20089:15 amRNSEPT Disclosure
2nd Jan 20087:45 amRNSEPT Disclosure
31st Dec 20078:58 amRNSEPT Disclosure
28th Dec 200710:06 amRNSEPT Disclosure
27th Dec 20078:37 amRNSEPT Disclosure
24th Dec 200710:10 amRNSRule 8.3-Premier Research Grp
24th Dec 20078:13 amRNSEPT Disclosure
21st Dec 20071:05 pmRNSRule 8.3- Premier Research
21st Dec 200711:15 amRNSRule 8.3- Premier Research
21st Dec 200710:34 amRNSEPT Disclosure
20th Dec 20072:40 pmPRNRule 8.3 - Premier Research plc
20th Dec 200712:07 pmRNSRule 8.3- Premier Research
20th Dec 200712:04 pmRNSRule 8.3- Premier Research
20th Dec 200711:04 amRNSEPT Disclosure
19th Dec 20073:59 pmRNSRule 8.3- Premier Research
19th Dec 20072:41 pmPRNRule 8.3 - Premier Research plc
19th Dec 200712:41 pmRNSRule 8.3- Premier Research
19th Dec 200711:03 amRNSEPT Disclosure
18th Dec 20072:45 pmRNSRule 8.3- Premier Research
18th Dec 200711:41 amRNSRule 8.3- (Premier Research )
18th Dec 20079:53 amRNSEPT Disclosure
17th Dec 20072:56 pmRNSRule 8.3-Premier Research Grp
17th Dec 20072:38 pmRNSRule 8.3- Premier Research
17th Dec 20072:17 pmRNSRule 8.3- Premier Research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.